Patent US4148876A successfully refreshed from Google Patents.
US4148876A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Biological preparations
Assignee: SmithKline Beecham Corp
•
Filing: 1978-03-01
•
Granted: 1979-04-10
•
Expires: 1998-03-01
Abstract
Abstract A novel antigenic preparation which comprises a plurality of microvesicles are unilamellar bodies comprising a single lipid bilayer upon the exterior surface of which is bound an antigenic protein derived from a virus and having a hydrophobic region.
Inventors
- 👤 June D. Almeida
- 👤 David C. Edwards
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 16:26
CPC Classifications
A; A61; A61K; A61K39/00; A61K39/12; A61K39/145; A61K39/39; A61K9/00; A61K9/10; A61K9/127; A61K9/1271; A61K2039/555; A61K2039/55511; A61K2039/55555; C; C12; C12N; C12N2760/00; C12N2760/00011; C12N2760/16011; C12N2760/16111; C12N2760/16134; Y; Y10; Y10S; Y10S424/00; Y10S424/812
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
56 words
An antigenic virosome preparation containing a plurality of microvesicles which microvesicles are unilamellar bodies having a single lipid bilayer upon the exterior surface of which is bound by hydrophobic bonding an antigenic protein, said antigenic protein being a hemagglutinin and neuraminidase sub-unit of a protective surface antigen derived from a myxovirus and having a hydrophobic region.
Claim 2
Dependent Claim
56 words
An antigenic virosome preparation containing a plurality of microvesicles which microvesicles are unilamellar bodies having a single lipid bilayer upon the exterior surface of which is bound by hydrophobic bonding an antigenic protein, said antigenic protein being a hemagglutinin and neuraminidase sub-unit of a protective surface antigen derived from a myxovirus and having a hydrophobic region.
Claim 3
Dependent Claim
17 words
An antigenic virosome preparation as claimed in claim 1 wherein the walls of the microvesicles contain lecithin.
Claim 4
Dependent Claim
17 words
An antigenic virosome preparation as claimed in claim 1 wherein the microvesicles contain cholesterol as a strengthener.
Claim 5
Dependent Claim
16 words
An antigenic virosome preparation as claimed in claim 1 wherein the virus is an influenza virus.
Claim 6
Dependent Claim
16 words
An antigenic virosome preparation as claimed in claim 1 wherein the microvesicles encapsulate an additional adjuvant.
Claim 7
Dependent Claim
23 words
An antigenic virosome preparation as claimed in claim 1 wherein the microvesicles are in the size range of 20 nm to 100 nm.
Claim 8
Dependent Claim
68 words
A pharmaceutical formulation which comprises an antigenic virosome preparation containing a plurality of microvesicles, which microvesicles are unilamellar bodies having a single lipid bilayer upon the exterior surface of which is bound by hydrophobic bonding an antigenic protein, said antigenic protein being a hemagglutinin and neuramidinase sub-unit of a protective surface antigen derived from a myxovirus and having a hydrophobic region, in association with an acceptable carrier therefor.
Claim 9
Dependent Claim
68 words
A pharmaceutical formulation which comprises an antigenic virosome preparation containing a plurality of microvesicles, which microvesicles are unilamellar bodies having a single lipid bilayer upon the exterior surface of which is bound by hydrophobic bonding an antigenic protein, said antigenic protein being a hemagglutinin and neuramidinase sub-unit of a protective surface antigen derived from a myxovirus and having a hydrophobic region, in association with an acceptable carrier therefor.
Claim 10
Dependent Claim
12 words
A formulation according to claim 7 wherein the carrier comprises a liquid.
Claim 11
Dependent Claim
10 words
A formulation according to claim 7 in unit dosage form.
Claim 12
Dependent Claim
19 words
A formulation according to claim 7 which is suitable for administration by a route selected from nasal and parenteral.
Claim 13
Independent Claim
75 words
A method for inducing antibody formation in a mammal, which comprises the administration to the mammal of a non-toxic antibody stimulating amount of an antigenic virosome preparation containing a plurality of microvesicles, which microvesicles are unilamellar bodies having a single lipid bilayer upon the exterior surface of which is bound by hydrophobic bonding an antigenic protein a hemagglutinin and neuraminidase sub-unit of a protective surface antigen derived from a myxovirus and having a hydrophobic region.
Claim 14
Independent Claim
75 words
A method for inducing antibody formation in a mammal, which comprises the administration to the mammal of a non-toxic antibody stimulating amount of an antigenic virosome preparation containing a plurality of microvesicles, which microvesicles are unilamellar bodies having a single lipid bilayer upon the exterior surface of which is bound by hydrophobic bonding an antigenic protein a hemagglutinin and neuraminidase sub-unit of a protective surface antigen derived from a myxovirus and having a hydrophobic region.
Claim 15
Independent Claim
76 words
A method for the prophylaxis of influenza in a mammal which comprises the administration to the mammal of a non-toxic, prophylactic amount of an antigenic virosome preparation containing a plurality of microvesicles, which microvesicles are unilamellar bodies having a single lipid bilayer upon the exterior surface of which is bound by hydrophobic bonding an antigenic protein having a hydrophobic region and a hemagglutinin and neuraminidase sub-unit of a protective surface antigen derived from an influenza virus.
Claim 16
Independent Claim
76 words
A method for the prophylaxis of influenza in a mammal which comprises the administration to the mammal of a non-toxic, prophylactic amount of an antigenic virosome preparation containing a plurality of microvesicles, which microvesicles are unilamellar bodies having a single lipid bilayer upon the exterior surface of which is bound by hydrophobic bonding an antigenic protein having a hydrophobic region and a hemagglutinin and neuraminidase sub-unit of a protective surface antigen derived from an influenza virus.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1982-04-09 | 1982-10-09 | 1983-04-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1986-04-09 | 1986-10-09 | 1987-04-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1990-04-09 | 1990-10-09 | 1991-04-10 | $7700.00 | Window Closed / Lapsed |